Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

• Iloperidone (Drug), also known as VYV-683, FANAPT: oral tablet

Primary outcomes

• Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period. [1 year]

Sex: All, ages: 12 Years to 17 Years

Inclusion Criteria:

* Patient is willing and able to provide assent and willing to complete all aspects of the study
* Patient's parent or legal guardian willing and able to provide consent
* Male or female patients 12 through 17 years of age (inclusive)
* Clinical diagnosis of either schizophrenia or bipolar I disorder

Exclusion Criteria:

* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
* A positive test for drugs of abuse